Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Cash & Current Investments (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Cash & Current Investments readings, the most recent being $17.4 million for Q4 2017.

  • On a quarterly basis, Cash & Current Investments rose 1436.07% to $17.4 million in Q4 2017 year-over-year; TTM through Dec 2017 was $17.4 million, a 1436.07% increase, with the full-year FY2017 number at $17.4 million, up 1436.07% from a year prior.
  • Cash & Current Investments hit $17.4 million in Q4 2017 for Eledon Pharmaceuticals, down from $19.2 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $105.5 million in Q3 2014 to a low of $1.1 million in Q4 2016.
  • Median Cash & Current Investments over the past 5 years was $23.6 million (2013), compared with a mean of $36.3 million.
  • Biggest five-year swings in Cash & Current Investments: plummeted 95.29% in 2016 and later soared 1436.07% in 2017.
  • Eledon Pharmaceuticals' Cash & Current Investments stood at $31.8 million in 2013, then skyrocketed by 231.48% to $105.3 million in 2014, then tumbled by 77.18% to $24.0 million in 2015, then plummeted by 95.29% to $1.1 million in 2016, then soared by 1436.07% to $17.4 million in 2017.
  • The last three reported values for Cash & Current Investments were $17.4 million (Q4 2017), $19.2 million (Q3 2017), and $22.6 million (Q2 2017) per Business Quant data.